Evaluation of COVID-19 Patients Complaining of Balance Disorders with the Dizziness Handicap Inventory

Yıl 2021, Cilt: 11 Sayı: 3, 500 - 506, 22.09.2021

Oğuz Kadir Eğilmez , Muge Ozcelik Korkmaz , Mehmet Güven

https://doi.org/10.31832/smj.941460

Öz

Objective:
Severe Acute Respiratory Syndrome-Coronovirus-2 (SARS-CoV-2), the Coronavirus Disease 2019 (COVID-19) agent, affects many systems in the body due to its rapidly developing nature and creates new findings every day. Loss of balance has recently begun to be identified as a clinical manifestation of COVID-19. In this study, the effects on the quality of life and the relationship between the degree of the disease were investigated by applying the “Dizziness Handicap Inventory” to patients who had COVID-19 and experienced balance problems during the active phase of the disease.
Materials and Methods:
Patients with COVID-19 were identified by being scanned digitally from the hospital registration system, and they were asked to participate in the survey by sending a "Google questionnaire" link. Patients who returned to the questionnaire and answered all questions were included in the study, and the data obtained were evaluated statistically.
Results:
Sixty four patients who answered all questions in the questionnaire were included in the study. Patients between the ages of 35-44 and 45-54 most frequently participated in the study. The mean for total inventory score was 35.90 ± 24.30 (min. 4-max. 88) in all patients. The inventory score means were higher in patients who were hospitalized and those with significant pathology on CT, and a statistically significant difference was also found (p<0.05).
Conclusion:
It should be kept in mind patients with COVID-19 may show disequilibrium symptoms and necessary precautions like prevention of falls in the elderly and additions of symptomatic treatment for dizziness should be considered.

Anahtar Kelimeler

COVID-19, Dizziness, Vertigo, Dizziness Handicap Inventory

Destekleyen Kurum

None

Proje Numarası

NA

Teşekkür

None

Denge Bozukluğu Bulunan COVID-19 Hastalarının Baş Dönmesi Engellilik Envanteri ile Değerlendirilmesi

Öz

Amaç:
Koronavirüs Hastalığı 2019 (COVID-19) ajanı olan Şiddetli Akut Solunum Sendromu-Koronovirüs-2 (SARS-CoV-2), hızla gelişen yapısı nedeniyle vücuttaki birçok sistemi etkilemekte ve her geçen gün yeni bulgular oluşturmaktadır. Denge kaybı, son zamanlarda COVID-19'un klinik bir belirtisi olarak tanımlanmaya başlandı. Bu çalışmada, hastalığın aktif döneminde COVID-19 olan ve denge sorunları yaşayan hastalara “Baş Dönmesi Engellilik Envanteri” uygulanarak yaşam kalitesi üzerine etkileri ve hastalığın derecesi arasındaki ilişki araştırılmıştır.
Gereç ve Yöntemler:
COVID-19 hastaları hastane kayıt sisteminden dijital olarak taranarak tespit edildi ve "Google anket" bağlantısı gönderilerek ankete katılmaları istendi. Ankete geri dönen ve tüm soruları cevaplayan hastalar çalışmaya dahil edildi ve elde edilen veriler istatistiksel olarak değerlendirildi.
Bulgular:
Anketteki tüm soruları yanıtlayan 64 hasta çalışmaya dahil edildi. Çalışmaya en sık 35-44 ve 45-54 yaşları arasındaki hastalar katıldı. Toplam envanter puanı ortalaması tüm hastalarda 35.90 ± 24.30 (min. 4-maks. 88) idi. Envanter skor ortalamaları, hastaneye yatırılan ve BT'de anlamlı patolojisi olanlarda daha yüksekti ve istatistiksel olarak anlamlı fark bulundu (p <0.05).
Sonuç:
COVID-19 hastalarının dengesizlik semptomları gösterebileceği akılda tutulmalı ve yaşlılarda düşmelerin önlenmesi ve baş dönmesi için semptomatik tedavi eklenmesi gibi gerekli önlemler alınmalıdır.

Anahtar Kelimeler

COVID-19, Dizziness, Baş Dönmesi, Baş Dönmesi Engellilik Anketi

Proje Numarası

NA

Kaynakça

• Reference1 Freni F, Meduri A, Gazia F, Nicastro V, Galletti C, Aragona P, et al. Symptomatology in head and neck district in coronavirus disease (COVID-19): A possible neuroinvasive action of SARS-CoV-2. Am J Otolaryngol 2020; 41: 102612. doi: 10.1016/j.amjoto.2020.102612.
• Reference2 World Health Organization. https://www.who.int/
• Reference3 Johns Hopkins University and Medicine (2020) Coronavirus resource center. https://coronavirus.jhu.edu/. (Accessed 6 December 2020).
• Reference4 Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362: 263-70. doi: 10.1016/S0140-6736(03)13967-0.
• Reference5 Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92: 552-5. doi: 10.1002/jmv.25728.
• Reference6 Wenting A, Gruters A, van Os Y, Verstraeten S, Valentijn S, Ponds R, et al. COVID-19 Neurological Manifestations and Underlying Mechanisms: A Scoping Review. Front Psychiatry 2020; 11: 860. doi: 10.3389/fpsyt.2020.00860.
• Reference7 Gautier JF, Ravussin Y. A New Symptom of COVID-19: Loss of Taste and Smell. Obesity (Silver Spring) 2020; 28: 848. doi: 10.1002/oby.22809.
• Reference8 Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci 2020; 11: 1206-9. doi: 10.1021/acschemneuro.0c00201.
• Reference9 Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci 2020; 413: 116832. doi: 10.1016/j.jns.2020.116832.
• Reference10 Liu K, Pan M, Xiao Z, Xu X. Neurological manifestations of the coronavirus (SARS-CoV-2) pandemic 2019-2020. J Neurol Neurosurg Psychiatry 2020; 91: 669-70. doi: 10.1136/jnnp-2020-323177.
• Reference11 Baig AM. Neurological manifestations in COVID-19 caused by SARS-CoV-2. CNS Neurosci Ther 2020; 26: 499-501. doi: 10.1111/cns.13372.
• Reference12 Finsterer J, Stollberger C. Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients. J Med Virol 2020: 10.1002/jmv.25903. doi: 10.1002/jmv.25903. Epub ahead of print.
• Reference13 Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol 2020; 70: 311-22. English, Spanish. doi: 10.33588/rn.7009.2020179.
• Reference14 Baig AM. Updates on What ACS Reported: Emerging Evidences of COVID-19 with Nervous System Involvement. ACS Chem Neurosci 2020; 11: 1204-5. doi: 10.1021/acschemneuro.0c00181.
• Reference15 Saniasiaya J, Kulasegarah J. Dizziness and COVID-19. Ear Nose Throat J 2020: 145561320959573. doi: 10.1177/0145561320959573. Epub ahead of print.
• Reference16 Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020; 77: 683-90. doi: 10.1001/jamaneurol.2020.1127.
• Reference17 Özçelik Korkmaz M, Eğilmez OK, Özçelik MA, Güven M. Otolaryngological manifestations of hospitalised patients with confirmed COVID-19 infection. Eur Arch Otorhinolaryngol 2020: 1–11. doi: 10.1007/s00405-020-06396-8. Epub ahead of print.
• Reference18 Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg 1990; 116: 424-7. doi: 10.1001/archotol.1990.01870040046011.
• Reference19 Tinetti ME, Gill TM. Dizziness among older adults: a possible geriatric syndrome. Ann Intern Med 2000; 132: 337-44.
• Reference20 Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med 2020; 202: 756-9. doi: 10.1164/rccm.202001-0179LE.
• Reference21 Ashrafi MR, Azizimalamiri R, Badv RZ, Tavasoli AR, Nikkhah A, Montazerlotfelahi H, et al. Coronavirus, its neurologic manifestations, and complications. Iran J Pediatr Epub 2020; 30: e102569. https://doi.org/10.5812/ijp.102569
• Reference22 Venhovens J, Meulstee J, Verhagen WIM. Acute vestibular syndrome: a critical review and diagnostic algorithm concerning the clinical differentiation of peripheral versus central aetiologies in the emergency department. J Neurol 2016; 263: 2151-7. https://doi.org/10.1007/ s00415-016-8081-8
• Reference23 Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al; COVID-19 Task Force of YO-IFOS. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 2020; 288: 335-44. doi: 10.1111/joim.13089.
• Reference24 Almufarrij I, Uus K, Munro KJ. Does coronavirus affect the audio-vestibular system? A rapid systematic review. Int J Audiol 2020; 59: 487-91. doi: 10.1080/14992027.2020.1776406.
• Reference25 Karadaş Ö, Öztürk B, Sonkaya AR. A prospective clinical study of detailed neurological manifestations in patients with COVID-19. Neurol Sci 2020; 41: 1991-5. doi: 10.1007/s10072-020-04547-7.
• Reference26 Viola P, Ralli M, Pisani D, Malanga D, Sculco D, Messina L, et al. Tinnitus and equilibrium disorders in COVID-19 patients: preliminary results. Eur Arch Otorhinolaryngol 2020: 1–6. doi: 10.1007/s00405-020-06440-7. Epub ahead of print.